01.05.2005 | Report
Differential sensitivities of trastuzumab (Herceptin®)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors
Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2005
Einloggen, um Zugang zu erhalten